In this study, our aim was to evaluate the angio-vasculogenic properties of human adipose tissue-derived mesenchymal stem cells overexpressing the granulocyte chemotactic protein (GCP)-2 (hASCs/GCP-2) and to determine possible therapeutic effects in an experimental ischaemic heart model.
Introduction
Despite recent breakthroughs in cardiovascular medicine, ischaemic cardiovascular disease remains one of the most serious health problems in Westernized society. 1 Owing to recent advancements in the field of stem cell biology, cell-based therapy has become an attractive novel strategy for the repair of damaged organs or tissues. have been widely studied due to the relative ease with which they can be isolated from patients. 2 -6 However, recent studies have identified some impediments, including a low survival rate for transplanted stem/progenitor cells demonstrated in an ischaemic heart. 7 -10 Chemotactic cytokines (chemokines) play a key role in immunity, homoeostasis, tumourigenesis, and angiogenesis. 11, 12 Granulocyte chemotactic protein-2 (GCP-2/CXCL6) has been reportedly expressed in mesenchymal cells, including endothelial cells and fibroblasts displaying angiogenic properties. 13 In particular, overexpressed GCP-2 in tumour cell allografts results in enhanced angiogenesis.
14 GCP-2 synergizes with MCP-1 chemokines, which are associated with angiogenesis in tumours and neutrophil mobilization. 15 Previously, our group demonstrated the role of GCP-2 and the interactions between GCP-2, MCP-1, and vascular endothelial growth factor (VEGF) in a hindlimb ischaemia model. 16 In this study, we hypothesized that overexpression of GCP-2 in stem cells could represent a novel strategy to enhance angiogenic and survival potential. This could increase their reported marginal influence on the repair of damaged tissues by inducing the secretion of pro-angiogenic chemokines/cytokines and pro-survival factors. We hereby report our evaluation of the angiogenic and anti-apoptotic properties of GCP-2 overexpressing human adipose tissue-derived mesenchymal stem cell (hASC/GCP-2) and their therapeutic potential in an acute myocardial infarction (MI) model. In addition, we investigated the endothelial transdifferentiation potential of hASC/GCP-2.
Methods
Additional materials and methods are available in the Supplementary material online.
Cell culture
Isolation of hASCs was performed as previously described. 16 All protocols involving human subjects were approved by the Institutional Review Boards of Dong-A University and Pusan National University, with all subjects providing informed consent. Cells were maintained at 378C under 5% CO 2 in culture medium [a-MEM, 10% foetal bovine serum (FBS), 100 U/mL of penicillin, and 100 mg/mL of streptomycin]. All experiments involved three to five passages of hASCs. Human umbilical vein endothelial cells (HUVECs) and normal human dermal fibroblasts (HDFs) were purchased from the ATCC (Manassas, VA, USA).
Viral vector construction and transduction
We used the hASC/GCP-2 cell line as previously reported. 16 Methods of viral vector construction and transduction are as described. 16 The GCP2 gene was obtained from the donor plasmid pCMV †SPORT6-GCP2 (21C Frontier human gene bank) and was recombined into the destination vector pLenti6/V5 using rapid BP/LR clonase (Invitrogen, Carlsbad, CA, USA). To verify the construct, the entire plasmids were sequenced. 293T cells, lipofectamine Plus (Invitrogen), and packaging mix (Invitrogen) were used for the replication-defective lentiviruses. Samples of the viruses were obtained at 48 or 72 h after transfection and filtered through a Millex-HV 0.45 mm PVDF filter (Millipore, Billerica, MA, USA). We transduced the hASCs for 6 h using viral supernatant in the presence of polybrene (5 mg/mL) and selected transductants by culture in blasticidin (10 mg/mL, Invitrogen).
Real-time polymerase chain reaction (PCR) and reverse-transcriptase PCR analyses
Quantitative real-time (qRT) -PCR assays were performed as described previously. 10, 17 In brief, total RNA was isolated from cells at passage 3 -5 by using RNA-stat (Iso-Tex Diagnostics, Friendswood, TX, USA) and RNA extraction kit (iNtRON Biotechnology, Korea) according to the manufacturer's instructions. Extracted RNA was subsequently reverse transcribed using Taqman Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. The synthesized cDNA was subjected to qRT-PCR or RT -PCR using human/mouse-specific primers and probes. RNA levels were quantitatively assessed using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Relative mRNA expression normalized to GAPDH expression was calculated as described previously. 10 Primer/ probe sets were purchased from Applied Biosystems.
Apoptosis assay
We induced apoptosis by serum deprivation for 6 h as previously described. 18 Apoptotic cells were examined using an Annexin V-FITC binding assay kit (Oncogene, San Diego, CA, USA) according to the manufacturer's protocol. Apoptotic cells were analysed using a FACScan (Becton Dickinson, San Jose, CA, USA).
Cell migration assay
To perform the cell migration assay, conditioned medium (CM) was collected as described previously. 19 Cells (1 × 10 6 each) were seeded into T-75 flasks and grown in normal medium or low-glucose DMEM (Gibco) containing 10% FBS, 100 U/mL of penicillin, and 100 mg/mL of streptomycin (Gibco) for 48 h until the cells reached 80% confluence. Culture media from each sample was then centrifuged at 1000 g for 10 min, with the supernatant collected and used as CM for the study. Briefly, HDFs were seeded to a final density of 1 × 10 5 /well in 24-well culture plates coated with type I collagen (0.2 mg/mL) and incubated at 378C in 5% CO 2 for 24 h to create confluent monolayers. The monolayers were scratched using a sterile pipette tip and incubated with CM. To measure cell mobility, we obtained pictures at five random fields 72 h after scratching. The wound area was examined by the wound margin and calculated using the NIH image program (http://rsb.info.nih. gov/nih-image/).
Induction of AMI and cell transplantation
The present study conforms to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) and conducted in accordance with the principles outlined in the Declaration of Helsinki for the use of human tissue or subjects. The mouse model of MI was prepared as previously described. 10, 20 All procedures were also approved by the Dong-A University Medical School Institutional Animal Care and Use Committee (DIACUC). Pain and distress were limited by the regular administration of analgesia in accordance with advice from the Dong-A Research Support Center for Medical Science. NOD/SCID mice (NOD.CB17-Prkdc scid /J strain, The Jackson Laboratory, Bar Harbor, Maine, USA), at 12-13 weeks of age, were randomly divided into five groups: hASCs, hASCs/GCP-2-treated group, anti-GCP-2-neutralizing antibodies treated hASCs/GCP-2 group (n ¼ 15 each), PBS group (n ¼ 15), and a sham-operation group underwent surgery without LAD ligation (n ¼ 15). All mice were anaesthetized (75 mg/kg ketamine, 1 mg/kg medetomidine, and 600 mg/kg atropine) and received buprenorphine (0.05 mg/kg), and the depth of anaesthesia was monitored by the respiratory rate and the lack of withdrawal reflex upon toe pinching. The trachea was endotracheally intubated, and mechanically ventilated using the Inspira-Advanced Safety Ventilator, which supplied 0.25-0.30 mL of room air 130 times per minute. The mouse was moved onto its right side, and the heart was exposed via a left thoracotomy. After removing the pericardium, the LAD was visualized using a stereomicroscope and occluded with a 9.0 nylon suture, which was placed at 0.3 mm distal to the atrioventricular junction. Occlusion was confirmed by observing the left ventricular pallor immediately after ligation. For tracking, cells were labelled with 4 mM chloromethylbenzamido-1,1
tetramethylindo-carbocyanine (CM-Dil) in a 100 mm culture dish at 2-3 × 10 6 cells per dish for 15 min at 37 and 48C before cell transplantation. Neutralizing antibodies against GCP-2 (R&D Systems) were added 1 h before transplantation. Following AMI, either 1 × 10 6 cells suspended in 50 mL of PBS or 50 mL of PBS alone was injected intramyocardially into three different places of the border zone of the infarction area. All surviving mice underwent echocardiography (ECHO) for the assessment of cardiac function at 4 weeks after the treatment of hASCs/GCP-2 or PBS and then sacrificed for histological analyses.
Measurement of cardiac function
Cardiac function was measured by an ECHO system with a 15 -16 MHz transducer (Sonos 4500, PHILIPS). Parasternal long-and short-axis views were obtained in both M-mode and two-dimensional echo images. Left ventricle end-diastolic diameter (LVEDD), left ventricle endsystolic diameter (LVESD), and left ventricular ejection fraction (LVEF) were assessed as previously described. 20 
Histological and immunohistochemical analysis
After completion of ECHO, all mice were sacrificed for histopathological analysis. Euthanasia was performed by iv injection of thiopental-sodium (40 mg/kg). After the perfusion of 4% paraformaldehyde (PFA, Sigma-Aldrich, St Louis, MO, USA) solution as described, 20 the heart was harvested and embedded in paraffin. Thereafter 5 mm transverse sections were serially collected through the entire left ventricle for a MassonTrichrome stain and immunohistochemical analysis. Four cross-sections, which were close to the mid-papillary position, were obtained from each harvested heart for the measurement of scar area and staining. Using a Scan Scope CS system (Aperio Technologies, Inc., Vista, CA, USA) with Image software, the scar-area stained blue by MassonTrichrome in each slide was quantitatively calculated as area units of millimetre square. To assess vascular density in the border zone of the infarction area, the number of microvessels was counted using a light microscope at ×400 magnification on five sections per heart, with a section close to the mid-papillary position stained with primary biotinylated ILB4 (1:250; Vector Laboratory, Inc.) and secondary streptavidin Alexa Fluor 488 (1:400; Invitrogen). Five high-power fields in each section were randomly selected, and the number of microvessels in each field was counted. The assessment of apoptosis in hearts was performed with the TUNEL assay kit (Promega) and stained with primary muscle actin with HHF35 (1:400; Dako) and secondary Cy3 (1:500; Jackson Immunoresearch Laboratories). Tissue sections were mounted, and then visualized using a laser scanning confocal microscope (LSM510, Carl Zeiss). To detect human cells, fluorescence in situ hybridization (FISH) was conducted using a Cy3-conjugated (Cambio, Cambridge, UK) human X chromosome probe.
Statistical analysis
All data were summarized as mean + SD or SE and analysed by Student's t-test for comparison between two groups, and multiple parameters were analysed using ANOVA with the Bonferroni post hoc test. Statistical significance was assumed at a value of P , 0.05. All statistical analyses were performed with SPSS version 12.0 software (SPSS, Inc., Chicago, IL, USA).
Results

Cell characterization
Cultured hASCs displayed spindle fibroblast-like morphology (Supplementary material online, Figure S1A ) which were used at passages 4-6 for all experiments. FACS analysis revealed that hASCs displayed MSC-specific characteristics, defined as positive for CD13, CD29, CD44, CD73, and CD105 and negative for CD34 and CD45 (Supplementary material online, Figure S1B ).
hASCs/GCP-2 exhibit high GCP-2 protein levels
To confirm the secretion of GCP-2 in hASCs/GCP-2, we performed ELISA. GCP-2 protein levels were detected significantly higher in the supernatant of GCP-2 transduced hASCs (hASCs/GCP-2) compared with the supernatant of control-vector transduced hASCs (hASCs) (1343 + 15 vs. 125 + 12.4 pg/mL; P , 0.001, n ¼ 7 each).
hASCs/GCP-2 exhibit angiogenic and anti-apoptotic properties
To investigate the angiogenic and anti-apoptotic properties of hASCs/ GCP-2, we conducted qRT-PCR. The expression of pro-angiogenic factors such as VEGF-A and hepatocyte growth factor (HGF) was more highly (each 29.9-and 2.1-fold) expressed in hASCs/GCP-2 compared with the control-vector transduced hASCs group ( Figure 1A ). Chemokines such as interleukin (IL)-8 and GCP-2, which play a pivotal role in neovascularization, were also significantly up-regulated (each 12.5-and 9.0-fold) in hASCs/GCP-2 compared with the control hASCs group. In addition, the expression of antiapoptotic/cell survival factors insulin-like growth factor (IGF)-1 and Akt-1 was also significantly higher (each 254.0-and 3.1-fold) in hASCs/GCP-2 when compared with the control hASCs group. To examine the cytoprotective effects of hASCs/GCP-2, an in vitro apoptosis assay was conducted. Results showed that there were significantly fewer apoptotic cells in the hASCs/GCP-2 compared with control hASCs and HUVECs groups ( Figure 1B) . Taken together, our data indicate that the hASCs/GCP-2 line expresses higher levels of both pro-angiogenic and anti-apoptotic genes.
3.3.1 Culture media from hASCs/GCP-2 promotes cell migration, proliferation, and the recovery of blood flow To measure whether proteins secreted from hASCs/GCP-2 can promote cell migration during the neovasculogenesis process, we performed an in vitro scratch assay. The assay demonstrated that hASCs/ GCP-2 CM significantly increased the rate of HDF wound closure compared with HUVECs and control-vector transduced hASCs at 72 h (20.2 + 2.1 vs. 37.9 + 4.9 and 50.9 + 4.6, respectively; n ¼ 4 each) (Figure 2A ). In addition, the proliferation rate of fibroblasts cultured in hASCs/GCP-2 CM was significantly higher than that of the control-vector transduced hASC or HUVEC CM ( Figure 2B) . Next, to clarify whether an in vivo paracrine mechanism was involved, the effects of secreted factors were investigated using an ischaemic hindlimb mouse model. LDPI analysis demonstrated that the rate of blood perfusion was significantly increased in the hASCs/ GCP-2 CM-injected limbs than those injected with either hASCs/ GCP-2-CM or control-CM at 21 days (Supplementary material online, Figure S2 ).
hASCs/GCP-2 exhibit high in vitro EC differentiation properties
To examine the EC differentiation potential of hASCs/GCP-2 and control-vector transduced hASCs, each cell type was cultured in EGM-2. After the hASCs/GCP-2 and hASCs differentiated to ECs on Day 10, we found an intriguing phenomenon; both hASCs/ GCP-2 and hASCs had spontaneously formed linear tubular structures, consistent with vasculogenesis (Supplementary material online, Figure S3A ). Specifically, hASCs/GCP-2 generated unique branching structures of tube, which appeared to differentiate into mature vascular-like tubes ( Figure 3A) . These tubular cells were stained for UEA-1 lectin and kinase insert domain receptor (KDR), which are EC-specific markers (Supplementary material online, Figure S3B and C ). Our immunocytochemistry results demonstrated that significantly higher numbers of hASCs/GCP-2 exhibited the EC marker UEA-1 lectin than hASCs, indicating a relatively high EC differentiation capacity of the hASCs/GCP-2 when compared with the hASCs (Supplementary material online, Figure S3D) .
Next, to measure the change of EC-specific gene expression during EC differentiation, we conducted RT -PCR. Undifferentiated hASCs/ GCP-2 and hASCs expressed endothelial nitric oxide synthase (eNOS) and Tie-2. Specifically, undifferentiated hASCs/GCP-2 exhibited a high level of Tie-2 ( Figure 3B and C ) . Ten days after EC Figure 1 Multiple angiogenic/anti-apoptotic expression patterns in hASCs/GCP-2. Gene expression levels of hASCs/GCP-2 and control groups were determined by qRT -PCR. Various angiogenic factors were up-or down-regulated in the hASCs/GCP-2 group compared with control groups. n ¼ 4 per group. differentiation of hASCs/GCP-2, the levels of Von Willebrand factor (vWF) expression was gradually elevated. Quantification of gene expression results demonstrated that the levels of eNOS, Tie-2, and vWF expression were significantly higher in hASCs/GCP-2 than hASCs at 5-15 days after EC differentiation ( Figure 3C ). Taken together, these results suggest that hASCs/GCP-2 possess an elevated potential for EC differentiation.
hASCs/GCP-2 exert favourable therapeutic effects in an MI model
To investigate the therapeutic potential of hASCs/GCP-2 in the ischaemic heart, we induced MI in NOD/SCID mice by coronary ligation and injected 1 × 10 6 cells directly into the peri-infarct zone of the ventricular wall. PBS was injected as a control (n ¼ 15 each (Figure 4) . In addition, transplantation of hASCs/GCP-2 significantly increased LVEF when compared with both control-vector transduced hASCs, whereas PBS and GCP-2 neutralized the hASCs/GCP-2 group (72.2 + 7.5 vs. 65.7 + 3.5%; P ¼ 0.022, vs. 48.1 + 5.0%; P , 0.001, vs. 63.1 + 8.3%; P ¼ 0.018). In addition, the hASCs/GCP-2-treated group showed significant reduction in the scar area when compared with the hASCs and PBS group ( Figure 5A ). The vascular density in the border zone of the infarct area was also significantly higher in the control-vector transduced hASCs/GCP-2-treated group vs. the hASCs and PBS group ( Figure 5B) . To investigate the therapeutic mechanism by which hASCs/GCP-2 injection induces cardiac repair, we measured the degree of cell death in the hypoxic border area of infarction. Apoptotic cells were detected by a terminal deoxynucleotidyl transferase-mediated dUTPbiotin nick end labelling (TUNEL) assay in both control groups and hASCs/GCP-2-treated groups over the course of 3 days. Triple staining for muscle actin confirmed that the apoptotic cells were myocytes and a highly significant difference was observed with hASCs/ GCP-2-treated hearts compared with control groups ( Figure 5C) . We, therefore, concluded that the bordering myocardium that is damaged after infarction may benefit from a protective effect arising from hASCs/GCP-2 transplantation.
Angiogenic factors are up-regulated after hASCs/GCP-2 transplantation
To determine the effects of hASCs/GCP-2 transplantation on cytokine expression in ischaemic hearts, post-MI mice were sacrificed and heart tissue was collected. The expression levels of VEGF-A and angiopoietin (Ang)-1 were significantly augmented in the hASCs/GCP-2-injected hearts compared with the control-vector transduced hASCs and PBS-injected hearts ( Figure 5D ).
Higher engraftment and transdifferentiation potential of hASCs/GCP-2
The engraftment or survival potential of the hASCs/GCP-2 was evaluated in an MI model using the NOD/SCID mice. A total of 1 × 10 6 Dil-labelled cells of each group was directly injected into the border areas of ischaemic heart. Immunohistochemistry results revealed that hASCs/GCP-2 exhibited a significantly higher engraftment potential (84.1 + 54.2) compared with control-vector transduced hASCs (152.3 + 52.5) ( Figure 6A ). In addition, flow cytometric analysis of enzymatically digested ischaemic heart was conducted to quantify the survival rate of transplanted cells in vivo 4 weeks after cell transplantation using a protocol previously described. 21 The quantification by flow cytometric analysis showed that hASCs/GCP-2 exhibited a significantly higher engraftment potential (0.47 + 0.28) compared with control-vector transduced hASCs (0.12 + 0.19) ( Figure 6B) . Next, to evaluate the EC differentiation capabilities of hASCs/ GCP-2 in vivo, we performed immunostaining against the EC protein isolectin B4 (ILB4). At 4 weeks after Dil-labelled cell transplantation, Angiogenic property of MSC overexpressing GCP-2 greater numbers of Dil and ILB4 double-positive cells were observed in hASCs/GCP-2-injected ischaemic heart when compared with control-vector transduced hASCs-injected ischaemic heart (4.8 + 2.1 vs. 1.3 + 1.2; P ¼ 0.006, n ¼ 7) ( Figure 6B ). Three-dimensional z-stacked images clearly demonstrated that a portion of the engrafted hASCs/GCP-2 were incorporated into vascular-like structures and expressed the EC marker, indicating endothelial differentiation of hASCs/GCP-2 ( Figure 6C) . To demonstrate whether these ILB4 expressing cells were truly derived from the transplanted hASCs/ GCP-2, FISH analysis using a human X chromosome was conducted. FISH results showed that these ILB4 positive cells present in the heart tissue originated from a human donor, confirming the transdifferentiation of hASCs/GCP-2 into EC (Supplementary material online, Figure S4 ).These results suggest that the hASCs/GCP-2 cell line possesses a higher cell survival and EC transdifferentiation potential in ischaemic heart tissue. 
Discussion
In this study, we aimed to demonstrate the potential therapeutic angiogenic properties of hASCs/GCP-2 and the possible mechanisms of their effects in an ischaemic cardiovascular disease model. Our main findings are the following: (i) pro-angiogenic and anti-apoptotic gene expression was enriched in hASCs/GCP-2; (ii) secreted factors from hASCs/GCP-2 enabled higher cell migration and proliferation potential; (iii) hASCs/GCP-2 differentiated into vascular tube-like cells consistent with EC morphology in vitro; (iv) the local transplantation of hASCs/GCP-2 resulted in better recovery of ischaemic heart tissue and increased angiogenic gene expression in vivo; (v) hASCs/ GCP-2 exhibited higher transdifferentiation, engraftment, and survival potential. To our knowledge, this experiment is the first to demonstrate the remarkable angio-vasculogenic properties of hASCs/ GCP-2 cells in an ischaemic heart disease animal model.
Chemokines have been known to play a key role in angiogenesis. 22 Recently, chemokines or cytokines secreted from injected hASCs were demonstrated to be an important paracrine phenomenon in an ischaemic animal model. 4,5 GCP-2 was originally isolated in CM from osteosarcoma cells 23 and reported to be expressed in mesenchymal cells including endothelial and fibroblast cells. In addition, there have been several studies demonstrating the angiogenic properties of GCP-2. 12,24 Therefore, we hypothesized that hASCs overexpressing chemokine GCP-2 may have the enhanced ability to repair or prevent the formation of damaged ischaemic tissue. Interestingly, Figure 5 Continued.
Angiogenic property of MSC overexpressing GCP-2 we found that hASCs overexpressing GCP-2 exhibited significantly higher pro-angiogenic genes such as VEGF-A, HGF, and IL-8. IL-8, also known as CXCL-8 and belonging to the CXC chemokine family, has been reported to regulate angiogenesis. 25 This result supports our previous data showing that GCP-2 affects the secretion of MCP-1 (CCL-2), which is a CC angiogenic chemokine in hASCs.
Another report suggests that GCP-2 and MCP-1 synergize to yield a 10-fold increase in chemotactic response. 13 We speculate that GCP-2 might function to express other pro-angiogenic genes, including chemokines, through an autocrine mechanism in hASCs. Our data indicate that GCP-2 may be one of the key modulators to enhance angiogenic processes, which is supported by cell migration and proliferation assays, since migration and proliferation are essential to angiogenesis. 26, 27 In line with the qRT -PCR data, the CM from hASCs/ GCP-2 significantly enhanced the migration and proliferation of fibroblasts. Currently, one of the major obstacles in using cell therapy for improved cardiac function is the low survival rate and poor engraftment of transplanted stem/progenitor cells in severe ischaemic heart tissues. We screened anti-apoptotic factor expression changes in hASCs overexpressing GCP-2. Interestingly, a significantly high rate of IGF-1 was expressed, which plays a crucial role in the survival of both injected and host cells in ischaemic environments. 28 We also found that hASCs/GCP-2 expressed significantly higher levels of Akt, which plays a pivotal role in the cell survival signalling pathway. 29 Akt has been known to prevent heart remodelling and repair the function of infarcted hearts. 30 Another highly expressed angiogenic chemokine, IL-8, was reported to enhance cell proliferation, survival, and inhibit apoptosis in endothelial cells. 31 As with our gene expression results, the in vitro apoptosis assays also demonstrated the high anti-apoptotic properties of hASCs/GCP-2 ( Figure 1B) . Consistent with the in vitro gene expression data, we also found that an increased number of hASCs/GCP-2 successfully engrafted and survived in vivo in the ischaemic heart tissues when compared with the hASCs 4 weeks after cell transplantation ( Figure 6A and B). These data support the notion that hASCs/GCP-2 possess enhanced cell survival properties.
The main therapeutic mechanisms involved in hASCs/GCP-2 transplantation in the ischaemic heart model are yet to be fully elucidated. Treatment of hASCs/GCP-2 in a murine model of MI revealed increased expression levels of the proangiogenic factor VEGF-A and Ang-1 in vivo and a higher ability of engraftment and survival potential of transplanted hASCs/GCP-2. This was concurrent with a significant increase in vascular density in the border zone of the infarction area. We hypothesize that the local injection of hASCs/GCP-2s may have stimulated circulating stem or progenitor cells to home-in on the damaged ischaemic tissue area, thereby contributing to a better therapeutic outcome due to the expression of pro-angiogenic chemokines such as GCP-2, IL-8, and MCP-1. 14 The controversy concerning the transdifferentiation potential of human BM-derived cells or MSCs 32 -35 prompted us to investigate the EC transdifferentiation potential of hASCs/GCP-2. To examine their endothelial differentiation capacity, we cultured them in the EC culture medium EGM-2. Intriguingly, hASCs/GCP-2 frequently formed vascular-like tube structures ( Figure 4A ) without the aid of Matrigel. Specifically, hASCs/GCP-2 was induced to form unique vascular tube structures with branching, which appeared to be a part of the mature EC differentiation process. These tubes were positively stained for lectin and KDR, confirming (at least partial) EC transdifferentiation. This is in agreement with our previous report involving vascular-like tube formation of human peripheral blood-derived CD31 positive cells. 15 Immunocytochemistry results revealed that a higher number of EC differentiated hASCs/GCP-2 clearly expressed the EC-specific protein lectin when compared with hASCs. Quantification of the serial gene expression results also demonstrated that EC-differentiated hASCs/GCP-2 highly expressed levels of EC-specific markers such as eNOS, Tie-2, and vWF. In vivo cell transplantation studies further confirmed the in vitro transdifferentiation data. Higher numbers of hASCs/GCP-2 were engrafted and expressing lectin in ischaemic heart tissues, indicating a higher capacity of EC transdifferentiation in hASCs/GCP-2. The robust EC differentiation properties of hASCs/GCP-2 could be correlated with a higher expression of VEGF-A, indicating a major role for this signalling pathway in autocrine effects of the vasculogenesis process. 36 In conclusion, we suggest that overexpression of GCP-2 in stem cells has the potential to enhance their angiogenic and survival properties. hASCs/GCP-2 offers an easily applicable and promising potential for novel treatments for ischaemic cardiovascular disease. Further studies are ongoing to test their overall suitability for clinical application, while ethical issues arising from their genetically engineered origin must also be addressed.
